Cargando…
1763P Daily chemotherapy and treatment unit in the COVID-19 era: Lessons of the first 60 days
Autores principales: | Aktas, B.Y., Guven, D.C., Degirmenciler, R.F., Taban, H., Aktepe, O.H., Kertmen, N., Kilickap, S., Dizdar, O., Aksoy, S., Erman, M., Yalçın, Ş., Turker, A., Arik, Z. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506466/ http://dx.doi.org/10.1016/j.annonc.2020.08.1827 |
Ejemplares similares
-
Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience
por: Demir, Metin, et al.
Publicado: (2022) -
1724P Changes in the outpatient and inpatient clinic admissions during COVID-19 pandemic: Anticipating and mitigating risks for cancer patients
por: Guven, D.C., et al.
Publicado: (2020) -
Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease
por: Yildirim, Hasan Cagri, et al.
Publicado: (2022) -
1612P Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy
por: Guven, D.C.C., et al.
Publicado: (2022) -
The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study
por: GÜVEN, Deniz Can, et al.
Publicado: (2021)